Assembly Biosciences, Inc.ASMBNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank50
3Y CAGR+95.5%
5Y CAGR-8.4%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

3Y CAGR
+95.5%/yr
vs -57.4%/yr prior
5Y CAGR
-8.4%/yr
Recent acceleration
Acceleration
+152.9pp
Accelerating
Percentile
P50
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
2 yr
Consecutive growthRecovering
PeriodValue
202515.88%
202414.38%
2023-30.12%
20222.12%
2021-35.85%
202024.56%
201917.89%
201864.48%
201733.64%
201680.27%